Protalix Biotherapeutics Inc (NYSEMKT:PLX) has announced that it would be releasing its financial results for the 1Q2017, as well as a corporate update, on May 10, 2017. The company has also stated that it would hold a conference call, on the same day. A replay of the call would...
Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...
May 06, 2015 OTC Disclosure & News Service - SILVER SPRING, Md., May 6, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the Institute of Virology at the...
Although a tremendous progress has been made, large full-thickness skin defects are still associated with mortality due to a low availability of donor skin areas. Autologous cultured epidermal autografts (CEA) were first to be used as an epidermal substitute; however, their functional and esthetic results were unsatisfying due to graft...
AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a...
Replicel Life Sciences (OTCQB: REPCF) The stem cell revolution is finally here, and it’s transforming modern medicine.  Investors are flocking to this small-cap company with treatments for hair restoration, skin rejuvenation, and tendon repair.  When we stumbled upon Replicel Life Sciences (OTCQB: REPCF and TSX.V:RP) it really caught our attention. ...
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) inked an alliance agreement with Novartis for development of their lead product, a drug called emricasan. The transaction was done with an upfront cost of $50 million and around $650 million to be paid in milestone payments in the times to come. Novartis gets emricasan’s rights...
Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...
Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...
In the last trading session, the stock price of Novavax, Inc. (NASDAQ:NVAX) gained over 14% to close the session at $1.62 on more than normal volume. No specific news accounts for this move. Last month, it commenced a Phase II clinical study evaluating the immunogenicity and safety of its...

Subscribe to our mailing list

* indicates required

Create a future where the human body can repair, restore, and rejuvenate itself

 

Trading Symbol

OTC: PLSI

The Next Big Global Cannabis Play